Abstract library

33 results for "biliary tree NET".
#1427 Uncinatectomy: Rethinking the Surgical Approach for Neuroendocrine and Intraductal Papillary Mucinous Neoplasms of the Pancreas
Introduction: Pancreatic neuroendocrine tumors (pNETs) and intraductal papillary mucinous neoplasms (IPMN) are increasingly recognized pancreatic tumors due to advances in imaging. Standard of care is surgical resection for these tumors is via the appropriate procedure: pancreaticoduodenectomy or enucleation.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: Student Anuj Arora
#2258 Cystic Duct Gastrinoma in a Patient with MEN1: A Case Report
Introduction: Gastrinomas are the most common functional enteropancreatic neuroendocrine tumour in MEN1 patients and are located almost exclusively in duodenum. Biliary tree gastrinomas are rare and accounted for 6 cases in literature. Only one of these cases was restricted to the biliary tree without associated duodenal gastrinomas.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: MD Eloa Brabo
#2946 Analysis of Factors Related to Gallstones in Patients with Neuroendocrine Tumors Treated with Long-Acting Somatostatin Analogues
Introduction: Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Zhirong Qi
Authors: Qi Z, Zhang Y, Li Y, Shi Y, ...
#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)
Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Thomas Couronne
Authors: Couronne T, Fine C, Hadoux J, Lecomte T, ...
#2831 Immunohistochemical Profile of Digestive Neuroendocrine Neoplasms: A Retrospective Analysis in a Single Algerian Institution
Introduction: Neuroendocrine Noplasms (NEN) are rare tumours, but their incidence is clearly increasing in our country due to the improvement of diagnostic means, in particular the generalization of immunohistochemical techniques. The digestive location represents more than 70% of the cases. The anatomopathological study enables to classify the NEN in different prognostic grades according to the degree of differentiation, mitotic index and Ki67.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Djihed Belabdi
#2855 Whole Exome Sequencing Reveals the Monoclonal Origin of Gastric Mixed Adenoneuroendocrine Carcinomas
Introduction: Gastric mixed adenoneuroendocrine carcinomas (g-MANECs) are rare neoplasms consisting of adenocarcinoma and neuroendocrine neoplastic components. G-MANECs show more malignant characteristics than gastric adenocarcinomas, while molecular mechanisms underlying the co-existence of the two components remains unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: M.D. Shida Yan
Authors: Yan S, Chen X, Zhang R, Song L, ...
#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#3027 Impact of Small Cell (SC) versus (vs.) Non-Small Cell (nSC) Morphology on Outcomes of Patients (pts) with Extra-Pulmonary, Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC)
Introduction: The 2018 SEER data indicates EP-PD-NEC morphology (SC vs. nSC) may impact patient outcomes.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Melissa Frizziero
#90 The prognostic value of FDG-PET scan in neuroendocrine tumors: a retrospective analysis of 46 patients treated in one center
Introduction: Neuroendocrine tumors (NETs) are rare and generally indolent. For diagnostic purposes, the sensitivity of FDG-PET scan is known to be low in this setting, though when positive, its prognostic value is not well-defined in NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
#137 Extensive ""multitasking"" surgery for advanced neuroendocrine tumors is safe and effective
Introduction: Management of advanced NETs is controversial, related to degree of intervention; the pendulum is swinging towards a more aggressive interventional approach. Our Center's philosophy is to offer a systematic, planned multimodality treatment for patients with advanced NETs.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD MICHAIL K Shafir